Background Many patients with bipolar disorder (BD) do not respond to or have difficulties tolerating lithium and/or other mood stabilizing agents. There is a need for personalized treatments based on biomarkers in guiding treatment options. The calcium voltage-gated channel CACNA1C is a promising candidate for developing personalized treatments. CACNA1C is implicated in BD by genome-wide association studies and several lines of evidence suggest that targeting L-type calcium channels could be an effective treatment strategy. However, before such individualized treatments can be pursued, biomarkers predicting treatment response need to be developed.

中文翻译：

---

双相情感障碍受试者中 CACNA1C、昼夜节律和应激反应分子的差异血清水平：与遗传和临床因素的关联

背景许多双相情感障碍（BD）患者对锂和/或其他情绪稳定剂没有反应或难以耐受。需要基于生物标志物的个性化治疗来指导治疗选择。钙电压门控通道 CACNA1C 是开发个性化治疗的有希望的候选者。全基因组关联研究表明 CACNA1C 与 BD 有关，并且多项证据表明，针对 L 型钙通道可能是一种有效的治疗策略。然而，在进行这种个体化治疗之前，需要开发预测治疗反应的生物标志物。